跳转至内容
Merck
CN

O2256

Sigma-Aldrich

奥索拉明 柠檬酸盐

别名:

5-(2-[二乙基氨基]乙基)-3-苯基-1,2,4-噁二唑

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C14H19N3O · C6H8O7
CAS Number:
分子量:
437.44
EC 号:
MDL编号:
UNSPSC代码:
12352100
PubChem化学物质编号:
NACRES:
NA.22
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

储存温度

2-8°C

SMILES字符串

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCc1nc(no1)-c2ccccc2

InChI

1S/C14H19N3O.C6H8O7/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-9H,3-4,10-11H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

InChI key

RBZIGQJSMCOHSS-UHFFFAOYSA-N

应用

Molecule involved in pharmacological studies including:
  • Antiinflammatory agents
  • Drugs that shift energy metabolism from mitochondrial respiration to glycolysis
  • Effect on warfarin anticoagulant properties

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Effect of oxolamine on cough sensitivity in COPD patients.
B B Ceyhan et al.
Respiratory medicine, 96(1), 61-63 (2002-02-28)
J McEwen et al.
The Medical journal of Australia, 150(8), 449-450 (1989-04-17)
Twenty reports in Australia, Belgium and The Netherlands have implicated oxolamine-citrate cough-mixtures as a cause of hallucinations in children of less than 10 years of age. Fever is not thought to be a likely alternative explanation. Similar reactions in older
Xuan Zhu et al.
Biopharmaceutics & drug disposition, 28(3), 125-133 (2007-02-14)
The possible reason for the significantly greater AUC of oral warfarin with oral oxolamine in male Sprague-Dawley rats was evaluated. After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10
[Therapeutic action of oxolamine in acute tracheo-bronchitis].
G Gunella et al.
La Clinica terapeutica, 100(5), 485-492 (1982-03-15)
L Kirilmaz et al.
Journal of microencapsulation, 9(2), 167-172 (1992-04-01)
One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel. However, a non-disintegrating tablet would be a better formulation to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持